American biotech industry lobbying for fewer Europe barriers

American biotechnology firms want U.S. trade negotiators to stress the need for a more flexible import process of genetically modified products as trade talks with the European Union pick up speed.

How to deal with genetically modified imports is the most contentious issue facing trade agreement negotiations between the U.S. and European Union this summer. “We need a trade agreement that is flexible and can accommodate technology,” said Matt O’Mara, director of foreign affairs for the Biotechnology Industry Organization. “We need technology. There is no more land. We need to use existing resources in a much more efficient way.”

Read the full, original post here: American biotech pushes for fewer Europe barriers

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend